New MSS-Elegible PDL1 Combo Trial (RO6895882, CEA-targetted IL2)

[DK37]

I think I have posted this MSS-eligible immunotherapy trial before but I noticed today that it has finally opened trial sites in the United States (previously it was Europe only) - so I wanted to repost. Your tumor needs to be CEA-positive. It combines a targeted form of IL-2 "RO6895882" (to activate the immune system in the vicinity of tumor) along with a PDL1 immunotherapy. It has trial locations in NYC and CT. I believe there can be a disconnect between CEA-expression on the tumor itself and what they measure floating in the blood stream - so I would not discard this trial possibility based upon bloodstream CEA results before talking to a MD at the trial. https://clinicaltrials.gov/ct2/show/NCT ... 673&rank=1

-DK

[juliej]

I believe there can be a disconnect between CEA-expression on the tumor itself and what they measure floating in the blood stream - so I would not discard this trial possibility based upon bloodstream CEA results before talking to a MD at the trial.

You're right: This study states : "The elevation of serum CEA and the expression of CEA in tissues did not show a direct correlation."

[DK37]

[quote="juliej"
You're right: This study states : "The elevation of serum CEA and the expression of CEA in tissues did not show a direct correlation."[/quote]


Great eyes Juliej!! Thanks!

-DK

[Stanfordmom]

Tom,
do you think this comb will work for KRAS mutant patients?

thanks,
Sha

[DK37]

Tom,
do you think this comb will work for KRAS mutant patients?

thanks,
Sha

Hi Sha,

My guess is that KRAS-status won't matter. If this drug strategy works (unknown, being tested right now), my guess is that it would work similarly between KRAS-wildtype and KRAS-mutant.

-DK